$OSTX Q2 '26 Earnings Results & Recap OS Therapies reported a net loss of $19.0 million for the six months ended June 30, 2026, with research and development expenses totaling $13.4 million during the same period.
$OSTX Q2 '26 Earnings Results & Recap OS Therapies reported a net loss of $19.0 million for the six months ended June 30, 2026, with research and development expenses totaling $13.4 million during the same period.